Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

ABSTRACT:

Background

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing and strongly associated with the metabolic syndrome, especially with obesity. A subtype, nonalcoholic steatohepatitis (NASH), might progress to advanced fibrosis and cirrhosis. NASH patients have an increased all-cause mortality. First and foremost are malignancies, followed by cardiovascular diseases.

Summary

The NAFLD fibrosis score and noninvasive liver stiffness measurement (transient hepatic elastography) are essential components for the diagnostic risk assessment of NAFLD patients. Other steatoses (alcohol, genetic disorders, drugs, toxins, malnutrition, etc.) must be considered in the differential diagnosis. So far, there is no approved liver-specific drug therapy with a proven effect

SUBMITTER: Roeb E 

PROVIDER: S-EPMC9082206 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature